A recognition of breakthrough regenerative technology for animal health
iC BIOSOLUTIONS is proud to receive the Innovation Award at BioFIT 2025, distinguishing our company as the most innovative project presented within the Animal Health track. This award acknowledges the strength, originality, and translational potential of our technology, a platform designed to transform the treatment of inflammatory and degenerative diseases in animals.
The technology behind the award:
Acellular regenerative biologics, a new paradigm
At the core of iC BIOSOLUTIONS’ innovation is our acellular regenerative technology, a cutting-edge approach designed to address the root causes of inflammatory and degenerative diseases. This technology builds on years of regenerative biology research and preclinical validation, and leverages the biological activity of regenerative processes without the use of living cells.
Rather than relying on whole-cell therapies, our technology focuses on cell-free biologics, offering:
- High biological precision
- Improved safety profiles compared to traditional cell-based interventions
- Enhanced consistency and manufacturability
This platform positions iC BIOSOLUTIONS at the forefront of next-generation biologics for animal health.
>> Learn more about our approach
First Application: Transforming treatment of equine arthritis
A high-impact entry point into veterinary medicine
The lead product candidate developed by iC BIOSOLUTIONS targets equine arthritis, one of the most widespread and debilitating conditions affecting horses. By directly targeting degenerative inflammation, our regenerative biologics aim to:
- Restore tissue function
- Reduce chronic pain and degradation
- Slow or reverse inflammatory deterioration
This equine-focused first application was a compelling element in the award decision, demonstrating both clinical relevance and market clarity.
>> Learn more about our applications
Expanding next into pet health
A platform designed for multi‑species deployment
Beyond the equine market, iC BIOSOLUTIONS’ technology is intentionally designed to expand across species. Following the success of the equine arthritis program, the next development wave will be directed toward pet health, addressing inflammatory conditions that affect companion animals.
This strategic expansion is enabled by the inherent versatility of our acellular regenerative platform, which supports adaptation across multiple animal health indications.
>> Learn more about our applications
This award reinforces our commitment to rewriting the future of inflammatory disease treatment through regenerative science. It also marks a key milestone for our team, validating the progress already achieved to date and strengthening our ambition to continue pushing boundaries in animal health innovation.
Dr Pascal SURUGUE
Co-Founder & CEO @ iC BIOSOLUTIONS